Seelos Therapeutics
Seelos Therapeutics is a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-12239733-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10869831-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10493023-B2
View Details
Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-12239733-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10869831-B2
View DetailsTreatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US-10493023-B2
View DetailsProducts
Intranasal racemic ketamine for acute suicidal ideation in MDD and PTSD
An intranasal small-molecule program developed for treating acute suicidal ideation and behavior in major depressive disorder and post-traumatic stress disorder; progressed into clinical study phases with topline data releases.
Gene therapy program for neurological and rare-disease indications
A gene therapy development program targeting CNS or rare-disease biology, undergoing preclinical and translational development.
Intravenous trehalose for neurodegenerative disease
An intravenous formulation of trehalose developed for evaluation in neurodegenerative disease clinical trials, including inclusion in a multi-arm platform trial.
Peptidic inhibitor therapeutic program
A development program advancing peptidic inhibitors as therapeutic candidates for relevant disease targets.
Protein-targeted autophagy therapeutic program
A program developing therapies that target protein homeostasis and autophagy pathways for treatment of neurologic or other diseases driven by protein aggregation.
SLS-005
Trehalose Injection, 90.5 mg/mL for Intravenous Infusion investigated for the treatment of Spinocerebellar Ataxia and ALS.
Intranasal racemic ketamine for acute suicidal ideation in MDD and PTSD
An intranasal small-molecule program developed for treating acute suicidal ideation and behavior in major depressive disorder and post-traumatic stress disorder; progressed into clinical study phases with topline data releases.
Gene therapy program for neurological and rare-disease indications
A gene therapy development program targeting CNS or rare-disease biology, undergoing preclinical and translational development.
Intravenous trehalose for neurodegenerative disease
An intravenous formulation of trehalose developed for evaluation in neurodegenerative disease clinical trials, including inclusion in a multi-arm platform trial.
Peptidic inhibitor therapeutic program
A development program advancing peptidic inhibitors as therapeutic candidates for relevant disease targets.
Protein-targeted autophagy therapeutic program
A program developing therapies that target protein homeostasis and autophagy pathways for treatment of neurologic or other diseases driven by protein aggregation.
SLS-005
Trehalose Injection, 90.5 mg/mL for Intravenous Infusion investigated for the treatment of Spinocerebellar Ataxia and ALS.
Services
Design and conduct of clinical studies including mid-stage (Phase 2) trials and participation in multi-arm platform trials.
Design and conduct of clinical studies including mid-stage (Phase 2) trials and participation in multi-arm platform trials.
Expertise Areas
- CNS therapeutics development
- Rare disease therapeutic development
- Clinical trial management and execution
- Intranasal drug delivery
Key Technologies
- Intranasal drug delivery
- Gene therapy vectors and delivery
- Intravenous formulation development
- Peptide therapeutics